ArticlemBio2022
Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane β-Lactamase Inhibitor To Augment β-Lactam Action.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 41 citations in OpenAlex.
- Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens forAntimicrobial agents and chemotherapy · 2026Article
- Synergistic activity of dual β-lactams againstMicrobiology spectrum · 2026Article
- The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates.The Journal of antimicrobial chemotherapy · 2026Article
- Single-domain antibodies as potent inhibitors of clinically relevantFrontiers in microbiology · 2026Article
- Breaking the barrier: from biosynthetic inhibition to multidimensional modulation of the mycobacterial cell wall in tuberculosis therapy.Frontiers in pharmacology · 2026Review
- A Review ofInternational journal of microbiology · 2026Review
- Response to "The promise and pitfalls: interpreting dual β-lactam success inASM case reports · 2026Article
- Loss-of-Function Mutations in the Penicillin-Binding Protein PonA1 Confer Agar-Dependent Resistance to Durlobactam inAntibiotics (Basel, Switzerland) · 2025Article
- Current Advances in Developing New Antimicrobial Agents Against Non-TuberculousAntibiotics (Basel, Switzerland) · 2025Review
- Oral β-lactam combinations are effectiveMicrobiology spectrum · 2025Article
- Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect againstMicrobiology spectrum · 2025Article
- Successful treatment of macrolide-resistantASM case reports · 2025Article
- Case report of peritoneal dialysis-associated peritonitis caused byASM case reports · 2025Article
- The promise and pitfalls: interpreting dual β-lactam success inASM case reports · 2025Article
- Sulbactam-Durlobactam Plus Ceftriaxone Dosing and Novel Treatment Regimens forbioRxiv : the preprint server for biology · 2025Article
- Novel C5α-substituted carbapenems enhanceAntimicrobial agents and chemotherapy · 2025Article
- The addition of amoxicillin improves the efficacy of the imipenem-avibactam combination againstAntimicrobial agents and chemotherapy · 2025Article
- Durlobactam in combination with β-lactams to combatAntimicrobial agents and chemotherapy · 2025Article
- Durlobactam to boost the clinical utility of standard of care β-lactams againstAntimicrobial agents and chemotherapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 11 institutions in 1 country.
Khalid M Dousa *Louis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0003-3272-7231
David C Nguyen *Division of Infectious Diseases and HIV Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.ORCID 0000-0001-5738-2976
Sebastian G KurzMount Sinai National Jewish Healthgrid.240341.0 Respiratory Institute, New York City, New York, USA.
Magdalena A TaracilaResearch Service, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Christopher R BethelResearch Service, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio, USA.
William SchinabeckBates College, Lewiston, Maine, USA.
Barry N KreiswirthCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.ORCID 0000-0002-0243-131X
Sheldon T BrownDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
W Henry BoomDivision of Infectious Diseases and HIV Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Richard S HotchkissDepartment of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Kenneth E RemyDivision of Pediatric Critical Care, UH Rainbow Babies & Children's Hospital, Cleveland, Ohio, USA.
Frank J JaconoLouis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
Charles L DaleyDivision of Mycobacterial and Respiratory Infections, National Jewish Healthgrid.240341.0, Denver, Colorado, USA.
Steven M HollandLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Alita A MillerEntasis Therapeutics, Waltham, Massachusetts, USA.ORCID 0000-0002-7110-0493
Robert A BonomoLouis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0002-3299-894X
Louis Stokes Cleveland VA Medical Center · USNational Jewish Health · USUniversity Hospitals of Cleveland · USBates College · USEntasis Therapeutics (United States) · USGeriatric Research Education and Clinical Center · USHackensack Meridian Health · USJames J. Peters VA Medical Center · USNational Institutes of Health · USRainbow Babies & Children's Hospital · USWashington University in St. Louis · US
Funding
Understanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MDissecting the molecular targets to overcome beta-lactam resistance in M. abscessus complexR01AI141805 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI BARRY Neal KREISWIRTH · 2019 to 2026
$5.1MUnderstanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9MA Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4MThe Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–BLRD VA I01 BX001974NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI100560NIAID NIH HHS R01 AI141805
Abstract
Mycobacterium abscessus (
Indexed as
beta-LactamsMycobacterium abscessusAmoxicillinAnti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase Inhibitorsbeta-LactamasesCefuroximeHumansImipenemMicrobial Sensitivity TestsAmoxicillinAnti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase Inhibitorsbeta-Lactamasesbeta-LactamsCefuroximedurlobactamImipenemantibiotic resistanceantibioticsbacteriadiazabicyclooctanedurlobactaminhibitorMycobacteriumMycobacterium abscessusβ-lactamase inhibitorβ-lactams
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.